Overview
FDA & Trial Timeline
10 eventsM.D. Anderson Cancer Center — PHASE1
Jessie L. Alexander — PHASE1, PHASE2
Harvoni: FDA approved
HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin, and genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin
M.D. Anderson Cancer Center — PHASE1
Descovy: FDA approved
DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 25 kg and less than 35 kg.
Children's Hospital Medical Center, Cincinnati — PHASE2
Cystaran: FDA approved
Treatment of corneal cystine crystal accumulation in patients with cystinosis
National Institute of Allergy and Infectious Diseases (NIAID)
Neutrexin: FDA approved
Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.
Cytovene: FDA approved
Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
3 availableDescovy
DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination wit…
DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 25 kg and less than 35 kg.
Cystaran
Treatment of corneal cystine crystal accumulation in patients with cystinosis
Neutrexin
Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfa…
Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
2 resourcesCytovene
Syntex (USA), Inc.
Travel Grants
No travel grants are currently matched to Adenovirus infection in immunocompromised patients.
Community
No community posts yet. Be the first to share your experience with Adenovirus infection in immunocompromised patients.
Start the conversation →Latest news about Adenovirus infection in immunocompromised patients
Disease timeline:
New recruiting trial: Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
A new clinical trial is recruiting patients for Adenovirus infection in immunocompromised patients
New recruiting trial: Third Party Viral Specific T-cells (VSTs)
A new clinical trial is recruiting patients for Adenovirus infection in immunocompromised patients
New recruiting trial: Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
A new clinical trial is recruiting patients for Adenovirus infection in immunocompromised patients
New recruiting trial: Viral Infections in Healthy and Immunocompromised Hosts
A new clinical trial is recruiting patients for Adenovirus infection in immunocompromised patients
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Adenovirus infection in immunocompromised patients
Are there clinical trials for Adenovirus infection in immunocompromised patients?
Yes — 3 recruiting clinical trials are currently listed for Adenovirus infection in immunocompromised patients on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Adenovirus infection in immunocompromised patients?
5 specialists and care centers treating Adenovirus infection in immunocompromised patients are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Adenovirus infection in immunocompromised patients?
3 patient support programs are currently tracked on UniteRare for Adenovirus infection in immunocompromised patients. See the treatments and support programs sections for copay assistance, eligibility, and contact details.